Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Litifilimab in Active Systemic Lupus Erythematosus (TOPAZ-1)
NCT04895241Phase 3Active, not recruiting
- Sponsor
- Biogen
- Start
- May 2021
- Primary completion
- Sep 2026
- Countries
- 15
01
Overview
A Phase 3 trial of litifilimab in systemic lupus erythematosus (SLE), sponsored by Biogen. Started May 2021; status: active, not recruiting.
02
Drugs
litifilimab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT04895241.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04895241.